infection data: why, when, and what to report?herpes simplex virus cytomegalovirus respiratory and...
TRANSCRIPT
INFECTION DATA: WHY, WHEN, AND WHAT TO REPORT?
Marcie Riches, MD, MS
Associate Member, BMT
Moffitt Cancer Center
Scientific Director, CIBMTR INWC
February 10, 2015
Overview
• Why is infection data important?
• Why is it so complicated?
• What to report
Can infections be prevented? • Updated guidelines published in 2009 for
infection prophylaxis1
• Prophylaxis and new antimicrobials have decreased early serious infections2
– CMV disease decreased by 48%
– GN bacteremia decreased by 39%
– Invasive mold infections decreased by 51%
– Invasive Candida infections decreased by 88%
• Later infections continue to remain a problem
1Tomblyn et al, BBMT and BMT, 2009
2Gooley et al, NEJM 2010
Acute
Neutropenia, barrier
breakdown (mucositis,
central venous access
devices)
Impaired cellular and
humoral immunity;
NK cells recover first, CD8 T
cell numbers increasing but
restricted T cell repertoire
Impaired cellular and
humoral immunity; B cell
& CD4 T cell numbers recover
slowly and repertoire diversifies
Bacte
rial
Fungal
Viral
Gram positive organisms Encapsulated bacteria
Gastrointestinal Streptococci species
Varicella Zoster virus
Aspergillus species Aspergillus species
Candida species
Pneumocystis
Phase I: Pre-engraftment Phase III: Late phase Phase II: Post-engraftment
Day 0 Day 15-45 Day 100 Day 365 and beyond
Mo
re c
om
mo
n
Les
s c
om
mo
n
(Seasonal/intermittent)
Graft-versus-host-disease:
Chronic
Gram negative bacilli
Herpes Simplex virus Cytomegalovirus
Respiratory and enteric viruses
EBV PTLD Other viruses eg. HHV
Immune Recovery following HCT
Storek, Expert Opinion on Biologic Therapy 2008
0
20
40
60
80
100
120
140
Imm
un
e c
ell c
ou
nts
(%
no
rma
l) Neutrophils, Monocytes, NK cells
B cells, CD8 T cells
CD4 T cells
Plasma cells, Dendritic cells
Upper normal limit
Lower normal limit
Weeks Months Years post HCT
Immune Reconstitution
• Quantitative Immunoglobulins—made by B-cells – IgG – IgM – IgA
• Immunodeficiency Panels – CD3 count (all T cells) – CD4 count (T cells) – CD8 count (T cells) – CD 19/20 count (B cells) – CD 56 count (NK cells)
• None of these assess FUNCTION of the cells
2100 R3, q55 - 76
Why are infection data so complicated?
• Numerous possible infections
• Antimicrobial medications used as
– Prophylaxis
– Pre-emptive therapy
– Empiric therapy
– Treatment of documented infection
• Multiple cultures and samples drawn
– What is really an infection?
Infectious disease markers
• Look for prior exposure! • Antibodies
– IgM: indicates recent infection—first antibody to develop with exposure • Ex. CMV IgM—new infection
– IgG: indicates prior infection—memory! • Ex. CMV IgG—past exposure
• What we check – EBV - Hepatitis B – CMV - Hepatitis C – HSV 1 and 2 - HTLV – VZV - HIV – Toxoplasma - WNV – Chaga’s - RPR
Exposure vs Infection
• Prior exposure – May or may not have caused symptoms
– Virus lies dormant • Can reactivate and cause symptoms in immune compromised
person
– Antibody markers (IgG)
• Infection – Active viral (infection) replication with/without disease
• **generally always treated**
– Assess with test to measure viral loads • Usually PCR
Where is the data to assess infection?
• Microbiology section: contains culture results
• Molecular pathology/immunology: PCR results for viral loads
• Pathology: histopathology or other tissue diagnoses for various infections
• Radiology: imaging studies, particularly for CT scan findings for fungal infections
• Progress notes
Infection Prophylaxis
• Usually include: – Antibiotics
• Quinolones
• Bactrim (TMP/SMX)
– Antifungals
– Antivirals
• Generally started about the time of conditioning to PREVENT infections
• Most centers have specific infection prophylaxis protocols/SOPs
Infection Prophylaxis 2100, R 3.0 Questions 260 – 289
How common are infections?
• >90% of patients likely to have at least one infection
• Many patients will have multiple infections
• 174/190 (91.6%) patients experienced 442 infectious episodes (1 – 11/patient)1
1Cordonnier et al, Transplantation 2006
“Clinically Significant Infection”
• Identified infections that result in a change of therapy with systemic antimicrobial agents
• Suspected infections with supporting clinical or radiographic findings (i.e. pulmonary infiltrate on chest CT)
– NOTE: Fever without documented infection (i.e. culture negative neutropenic fever) is NOT an infection
Infection Reporting
Sites of Infection
**Disseminated infections must have the organism identified at 3 or more non-contiguous sites
So What’s NOT an Infection?
• Culture-negative neutropenic fever without clear source
• Upper respiratory infections that are presumed viral but no virus identified
• Stool/Oral Candida
• Toe nail Fungus
What is the same infection? (i.e. don’t report again)
Bacteria Virus Fungal
≤7 days
• All bacteria (except Clostridium Difficile)
≤30 days
• Clostridium Difficile
≤ 365 days
• Helicobacter pylori
≤14 days
• VZV
• HZV
• Adenovirus
• Enterovirus
• Influenza virus
• Parainfluenza
• Rhinovirus
≤60 days
• CMV
• HSV
• Polyomavirus
• EBV
≤14 days
• Yeasts
Candida
Cryptococcus
≤90 days
• Molds
Aspergillus
Fusarium
Mucor
Infections with Supplemental Data
• Mold infections (2046/2146)
– Aspergillus - Fusarium
– Mucormycosis - Rhizopus
– Zygomycetes
• Viral Hepatitis (2047/2147)
– Hepatitis B
– Hepatitis C
• HIV (2048/2148)
Definitions of Fungal Infection
• Proven – Organism seen on pathology with associated tissue damage
– Organism identified by culture from a sterile procedure from a sterile area with associated clinical/radiologic findings of infection
• Probable – Requires 1 host factor + 1 clinical factor + 1 microbiologic factor
• Possible – Requires 1 host factor + 1 clinical factor
– No microbiologic factor needed
Clin Infect Dis. 2008 June 15; 46(12): 1813–1821
Host Factors
• Recent neutropenia for >10 days associated with the onset of fungal disease
• Receipt of allogeneic transplant
• Steroid use of >0.3mg/kg/day for >3 wks
• Treatment with T-cell immune suppressive meds in prior 90 days – i.e. Cyclosporine, CAMPATH, Fludarabine
• Inherited severe immune deficiency
Clin Infect Dis. 2008 June 15; 46(12): 1813–1821
Clinical Factors
• Lower Resp Tract –CT findings of well-defined
nodule, wedge shaped infiltrate, air-crescent, or cavity, OR
–Nonspecific nodule(s) with pleural rub, pleural pain, or hemoptysis
• Tracheobronchitis –Ulceration, nodule,
pseudomembrane, eschar, or plaque seen on bronch
• Sinonasal Infection – Imaging with sinusitis plus
either acute localized pain, nasal ulcer or black eschar, or extension beyond bony borders
• CNS –Focal CNS lesions
–Meningeal enhancement
• Disseminated candidiasis –Target lesions in liver and/or
spleen
Clin Infect Dis. 2008 June 15; 46(12): 1813–1821
Microbiologic Factors
Cytology, Direct Microscopy, or Culture – Sputum, BAL, or bronchial
brush findings with fungal elements by culture or direct observation
– Sinus aspirate with findings of fungal elements by culture or direct observation
– Skin ulcerations require both culture and direct observation of fungal elements
Detection of Antigen, cell wall, or nucleic acids –Galactomannan: single positive
in serum, plasma, pleural fluid, BAL, or CSF
–Beta-D-glucan: single serum sample positive
–PCR for nucleic acids are NOT considered
Clin Infect Dis. 2008 June 15; 46(12): 1813–1821
Fungal Insert
• To obtain more specific information about mold infections
• Requests detailed information of
– Diagnosis
• Date of infection, site of infection, diagnostic tests
– Prophylaxis and Therapy • Fungal drugs at the time of diagnosis
• Therapy up to 6 months after diagnosis
Mold infection (2046/2146)
Therapy Example
*If treatment held for less than 7 consecutive days and then restarted, do not consider as “Therapy Stopped”
Viral Hepatitis Insert (2047/2147)
• Viral Hepatitis may be a chronic infection of the liver
–Viral particles can be found in the blood stream
–May lead to cirrhosis or hepatocellular carcinoma
–May be lymphomagenic
• Goal: Collect detailed information on antiviral therapy and viral loads in HCT patients
Viral Hepatitis B • HBsAb = Hepatitis B surface antibody
– Develops in patients immunized against HBV – Develops in patients infected with HBV
• HBcAb = Hepatitis B core antibody – NOT seen in patients immunized – Occurs in a patient infected with HBV who successfully made antibodies – Often not seen in chronic HBV hepatitis
• HBsAg = Hepatitis B surface antigen – NOT seen in patients immunized – Indicates ongoing viral replication with potential to infect others
• HBV DNA = Hepatitis B viral load – Ongoing viral replication – PCR test
Example
• Patient AB:
– HBcAb positive
– HBsAb positive
– HBsAg negative
• Patient YZ:
– HBcAb negative
– HBsAb positive
– HBsAg negative
Which patient had a prior infection with Hepatitis B?
Viral Hepatitis C
• HCAb = Hepatitis C antibody
– Prior exposure to hepatitis C
– **NO Immunization available**
• HCV RNA = Hepatitis C viral load
– Ongoing viral replication
– Infective potential
• Diagnostic test
• Viral Load levels
• Treatment
• CD4 counts (HIV only)
• Liver pathology (Viral Hepatitis Only)
Key Data Elements: Hepatitis and HIV forms
Questions